Yasmeen Rahimi

“An amazing year and more to come for next year. I guess my question is, you know, like 2027 is right around the corner. It could be a very big year for Immunivand with GRAVES and MG data.”

“Maybe you would love to understand with Maple coming onto the label, how soon it could actually change the pair's views on Actually, removing the requirement of being on a beta blocker and making my course that is the first choice and therefore could increase the potential time of patients and uptake would appreciate…”

“An outstanding quarter and also giving guidance, closer fine-tuning, narrowing down the Meister outcome study.”

“I am so sorry for the technical difficulties in creating to my colleagues and you guys. Team, obviously, this data is absolutely outstanding. How has it changed your view in terms of the inclusion-exclusion of the patients that you'll be enrolling?”

“Congrats on getting the alignment of the NSAA setting, kicking that off, so congrats and great updates. You guys do always a wonderful job helping us think about the next catalyst in terms of, you know, thinking about timing, the type of data we will get, and the expectation.”